SCHEMBL41499

SCHEMBL41499

COc1ccc(Cl)c(B(O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 4/20 0.48
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
TDP1 Q9NUW8 2/20 0.41
MAPT P10636 3/20 0.41
RAB9A P51151 1/20 0.41
CA12 O43570 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CA14 Q9ULX7 2/20 0.40
ERN1 O75460 1/20 0.40
TRIM24 O15164 1/20 0.40
TYR P14679 1/20 0.40
TRIM33 Q9UPN9 1/20 0.40
KMT2A Q03164 2/20 0.40
TYK2 P29597 1/20 0.40
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2A6 P11509 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29469134 1.00 ENPP2 (0.48) ENPP2CA1CA2TDP1MAPT
SCHEMBL29807652 0.83 ENPP2 (0.48) ENPP2CA1CA2TDP1MAPT
SCHEMBL41797 0.83 ENPP2 (0.48) ENPP2CA1CA2TDP1MAPT
SCHEMBL29952344 0.79 NQO1 (0.46) TDP1MAPTERN1KMT2AALDH1A1
SCHEMBL29953057 0.79 ALDH1A1 (0.44) MAPTRAB9AKMT2AALDH1A1KDM4E
SCHEMBL17592670 0.79 ALDH1A1 (0.44) MAPTRAB9AKMT2AALDH1A1KDM4E
SCHEMBL544415 0.79 NQO1 (0.46) TDP1MAPTERN1KMT2AALDH1A1
SCHEMBL27192252 0.78 KDM4E (0.44) TDP1ALDH1A1KDM4EGAAMCL1
SCHEMBL18230240 0.78 TDP1 (0.34) ENPP2CA1CA2TDP1MAPT
SCHEMBL3993839 0.77 FFAR4 (0.41) TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114763349-B Organic compound, application and preparation method thereof and organic electroluminescent device using same 北京鼎材科技股份有限公司 2026-05-22 CN claimed
CN-114763349-A Organic compound, application and preparation method thereof and organic electroluminescent device adopting organic compound 北京鼎材科技有限公司 2022-07-19 CN claimed
CN-114763349-B Organic compound, application and preparation method thereof and organic electroluminescent device using same 北京鼎材科技股份有限公司 2026-05-22 CN disclosed
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECH LIMITED (GB) 2026-05-21 US disclosed
EP-4426683-B1 BENZODIAZEPINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE GABA A GAMMA1 RECEPTOR HOFFMANN LA ROCHE (CH) 2026-04-01 EP disclosed
US-20260070912-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN-LA ROCHE INC. (US) 2026-03-12 US disclosed
US-20260022099-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2026-01-22 US disclosed
US-20250388586-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM HOFFMANN LA ROCHE (US) 2025-12-25 US disclosed
EP-4116302-B1 COMPOUND AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN PREPARATION OF THERAPEUTIC ANTI-CANCER DRUG TIANJIN JIKUN MEDICAL TECH CO LTD (CN) 2025-10-29 EP disclosed
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
EP-4622967-A1 COMPOUNDS THAT INHIBIT PKMYT1 Exelixis, Inc. (US) 2025-10-01 EP disclosed
WO-2007073283-A1 SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS ASTRAZENECA AB (SE) 2007-06-28 WO disclosed
US-20070142328-A1 Compounds and Uses Thereof ASTRAZENECA AB (SE) 2007-06-21 US disclosed
US-20070142382-A1 Compounds and Uses Thereof ASTRAZENECA AB (SE) 2007-06-21 US disclosed
WO-2007052123-A2 PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2007-05-10 WO disclosed
US-20070105872-A1 N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide PFIZER LIMITED 2007-05-10 US disclosed
WO-2007002313-A2 PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 WO disclosed
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 US disclosed
US-20050245524-A1 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2005-11-03 US disclosed
WO-2005096784-A2 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER EGFR, KRAS, O60361 ENPP2 4624/4885CA1 3692/4885CA2 2064/4885
US-20070105872-A1 N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide P2RX5, P2RX3, AADAC ENPP2 1415/4885CA1 1700/4885CA2 238/4885
US-20250388586-A1 NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM GABRA1, GABRB1, GABRA6 ENPP2 4804/4885CA1 254/4885CA2 326/4885
US-20070142328-A1 Compounds and Uses Thereof MAPT, BDNF, PYGB ENPP2 879/4885CA1 140/4885CA2 2291/4885
US-20070142382-A1 Compounds and Uses Thereof MAPT, BDNF, PYGB ENPP2 879/4885CA1 140/4885CA2 2291/4885
US-20070003539-A1 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants F12, F11, F7 ENPP2 662/4885CA1 3281/4885CA2 3011/4885
US-20260022099-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, NR1H4, CNR1 ENPP2 965/4885CA1 2945/4885CA2 3205/4885
US-20050245524-A1 Benzotriazine inhibitors of kinases SRC, CAMK4, CAMK2G ENPP2 1856/4885CA1 3214/4885CA2 247/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 ENPP2 816/4885CA1 685/4885CA2 1916/4885
US-20260070912-A1 BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM GABRA1, GABRB1, GABRA6 ENPP2 4831/4885CA1 273/4885CA2 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.